Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint
1. SMMT's Phase 3 HARMONi trial met its PFS primary endpoint. 2. Ivonescimab showed improvement in PFS but not statistically significant OS. 3. A BLA filing for ivonescimab is being considered by Summit. 4. Safety profile of ivonescimab + chemotherapy was manageable. 5. SMMT stock fell 12.3% to $23 in premarket trading.